Ann: Trading Halt, page-18

First 18 Last

Share
Profile

Follow
Cidkiddd94

383 Posts.

45

07/12/23

09:38

Post #: 71318377
Share

Originally posted by MikesLM: ↑

Let's trust in AF and management to make strategic acquisitions at the appropriate time to accelerate growth for the long term.

Imbio is growing very quickly and is cash-flow positive and probably wouldn't go for this price next year or the year after when its revenue is much higher (and potential profitability) and the acquisition would probably significantly enhance 4DMedical's products and company's profile.

Imbio would also have a large customer list that we can leverage to upsell 4DMedical's suite / pipeline of products.

If you look at Imbio's product suite, you will see a large array of lung analysis products (and FDA cleared where applicable). And a heart product (coronary artery analysis) too!

At first sight and when you see capital raise it might sound curious as to "why", but when you look further (and I'm sure the company will fully explain this), you will find that this is money very well spent for A$30m (and potentially cheap on a LT basis). If you think about the money we would need to spend to conduct R&D to produce or reproduce all these products and then money to achieve FDA approvals for the products and then the marketing/commercialisation costs to get the company to $9m revenue per year and growing at 112 per cent, you'd see that this is great value for money!!

We are also taking out potential similar competition. Remember PME acquired Visage and turned that into a real money spinner and to the company of its multi billion dollar market cap. It also makes sense why we met Minnesota governor and trade delegation in Melbourne recently.

All in all, after reflecting about this with high level research, and keen to see the company's presentation on the rationale, I think investors should see this as a very good acquisition, and potentially material/game-changing for the company's sustainable future.

Expand

110% agree with you.
Already at profitability at a growth rate of 112%, which 4D could increase that growth rate whilst accelerating 4D's reach and customer base.
I think it's a very good move. AF knows

4DX Price at posting: 95.5¢ Sentiment: Buy Disclosure: Held
15 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 103 more messages in this thread...

First 18 Last

Add 4DX (ASX) to my watchlist

(20min delay)
Last 52.5¢		Change -0.005(0.94%)		Mkt cap ! $209.3M

Open	High	Low	Value	Volume
52.5¢	53.0¢	50.5¢	$222.3K	429.2K

Buyers (Bids)

No.	Vol.	Price($)
1	57	52.5¢

Sellers (Offers)

Price($)	Vol.	No.
53.0¢	32671	4

View Market Depth

No.	Vol.	Price($)
1	57	0.525
5	17700	0.520
2	34776	0.515
4	23061	0.510
10	56679	0.505

Price($)	Vol.	No.
0.530	32671	4
0.535	76248	3
0.540	15211	3
0.545	38006	3
0.550	54440	3

Last trade - 12.41pm 07/10/2024 (20 minute delay)

4DX (ASX) Chart

Ann: Trading Halt, page-18

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-18

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News